INMD Stock Forecast 2025-2026
Distance to INMD Price Targets
INMD Price Momentum
🤔 Considering Inmode (INMD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest INMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, INMD has a neutral consensus with a median price target of $20.50 (ranging from $16.00 to $29.00). Currently trading at $18.31, the median forecast implies a 12.0% upside. This outlook is supported by 3 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 58.4% upside. Conversely, the most conservative target is provided by Caitlin Cronin at Canaccord Genuity, suggesting a 12.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INMD Analyst Ratings
INMD Price Target Range
Latest INMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 5, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $29.00 |
| Feb 4, 2025 | Needham | Mike Matson | Hold | Maintains | $0.00 |
| Jan 9, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $26.00 |
| Oct 31, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 21, 2024 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Oct 17, 2024 | BTIG | Sam Eiber | Buy | Initiates | $25.00 |
| Oct 14, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $27.00 |
| Oct 10, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Sep 27, 2024 | Raymond James | Outperform | Initiates | $0.00 | |
| Aug 22, 2024 | Scotiabank | Sector Outperform | Initiates | $0.00 | |
| Jul 23, 2024 | Jefferies | Matthew Taylor | Hold | Downgrade | $19.00 |
| Jul 15, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $29.00 |
| Jul 12, 2024 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $16.00 |
| Jul 11, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| May 3, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Apr 12, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $33.00 |
| Apr 9, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 15, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $34.00 |
| Feb 14, 2024 | UBS | Danielle Antalffy | Neutral | Maintains | $26.00 |
| Jan 18, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $32.00 |
InMode Ltd. (INMD) Competitors
The following stocks are similar to Inmode based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InMode Ltd. (INMD) Financial Data
InMode Ltd. has a market capitalization of $1.27B with a P/E ratio of 8.1x. The company generates $394.82M in trailing twelve-month revenue with a 45.9% profit margin.
Revenue growth is -22.8% quarter-over-quarter, while maintaining an operating margin of +28.5% and return on equity of +24.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
InMode Ltd. (INMD) Business Model
About InMode Ltd.
Provides innovative medical technologies in aesthetics.
The company designs and manufactures minimally invasive aesthetic healthcare solutions, generating revenue through sales to clinics and practitioners globally. Its products utilize advanced technologies in radiofrequency, light, and laser, addressing the increasing demand for effective and low-downtime aesthetic procedures.
Founded in Israel, InMode Ltd. has become a key player in the aesthetic medical device industry, focusing on facial and body contouring, skin rejuvenation, and women's health. The company continues to drive growth and innovation in the market by advancing non-invasive treatment options.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
599
CEO
Mr. Moshe Mizrahy
Country
Israel
IPO Year
2019
Website
www.inmodemd.comInMode Ltd. (INMD) Latest News & Analysis
InMode Responds to Doma Perpetual's Letters
9 days agoInMode Ltd. responded to DOMA Capital Management regarding its capital allocation strategy and commitment to shareholder returns, refuting misconceptions about staffing and production.
InMode's clarification on capital allocation and shareholder returns signals financial stability and commitment to investors, potentially boosting confidence and stock performance.
InMode Ltd. (Nasdaq: INMD) will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, featuring CFO Yair Malca in an in-person fireside chat.
InMode Ltd.'s participation in key investor conferences signals its commitment to transparency and engagement, potentially influencing investor confidence and stock performance.
InMode is undervalued, with strong cash flow and growth potential from international expansion and the non-invasive plastic surgery market. Stock buybacks and investments may enhance financial stability.
InMode's undervaluation, strong cash flow, and growth in a booming market indicate potential for stock price appreciation and increased financial stability through strategic investments.
InMode Ltd. (NASDAQ: INMD) will hold its Q4 2024 earnings results conference call on February 4, 2025, at 8:30 AM ET, featuring key executives and analysts from various firms.
The Q4 2024 earnings call for InMode Ltd. will provide insights into financial performance and future guidance, influencing investor sentiment and stock valuation.
InMode Ltd. reported Q4 GAAP revenues of $97.9 million and full-year revenues of $394.8 million for 2024. The company returned $285.4 million to shareholders, with a new share repurchase program of 10%.
Strong revenue growth and significant shareholder capital return indicate financial health and commitment to maximizing shareholder value, potentially driving stock performance higher.
InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
1 month agoInMode Ltd. (Nasdaq: INMD) CFO Yair Malca will host investor meetings at the BTIG MedTech Conference in Snowbird, UT on February 12, 2025.
Yair Malca's presentation at a key industry conference may provide insights into InMode's financial health and growth prospects, influencing investor sentiment and stock performance.
Frequently Asked Questions About INMD Stock
What is InMode Ltd.'s (INMD) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, InMode Ltd. (INMD) has a median price target of $20.50. The highest price target is $29.00 and the lowest is $16.00.
Is INMD stock a good investment in 2025?
According to current analyst ratings, INMD has 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INMD stock?
Wall Street analysts predict INMD stock could reach $20.50 in the next 12 months. This represents a 12.0% increase from the current price of $18.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InMode Ltd.'s business model?
The company designs and manufactures minimally invasive aesthetic healthcare solutions, generating revenue through sales to clinics and practitioners globally. Its products utilize advanced technologies in radiofrequency, light, and laser, addressing the increasing demand for effective and low-downtime aesthetic procedures.
What is the highest forecasted price for INMD InMode Ltd.?
The highest price target for INMD is $29.00 from Matt Miksic at Barclays, which represents a 58.4% increase from the current price of $18.31.
What is the lowest forecasted price for INMD InMode Ltd.?
The lowest price target for INMD is $16.00 from Caitlin Cronin at Canaccord Genuity, which represents a -12.6% decrease from the current price of $18.31.
What is the overall INMD consensus from analysts for InMode Ltd.?
The overall analyst consensus for INMD is neutral. Out of 11 Wall Street analysts, 3 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $20.50.
How accurate are INMD stock price projections?
Stock price projections, including those for InMode Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
